FDA panel of advisers backs GlaxoSmithKline seizure drug, despite side effects

more images

more images

FDA panel favors Glaxo epilepsy drug

WASHINGTON — Federal health advisers say GlaxoSmithKline’s epilepsy drug Potiga appears effective in controlling seizures.

An agency spokeswoman said the Food and Drug Administration’s panel of neurologists voted unanimously that company studies showed the effectiveness of the drug. The panelists noted side effects, including the inability to urinate, but said they could be controlled by carefully monitoring patients.

British drugmaker GlaxoSmithKline PLC has asked the FDA to approve the pill for epilepsy patients who continue experiencing seizures while taking other medications.

Epilepsy drugs already on the market include Johnson & Johnson’s Topamax and Pfizer Inc.’s Neurontin.